Mayo Clinic study underscores potential value of RABI-767
Lamassu Pharma announced the development of its lead therapeutic compound, RABI-767, may fulfill the unmet clinical need for the treatment of patients with pancreatitis, according to a press release.
RABI-767 is a novel small molecule lipase inhibitor that is injected directly into the pancreas; in preclinical studies, it decreased the breakdown or release of unsaturated fats and saturated fats during acute pancreatitis attacks. The value of this therapeutic was underscored by recent Mayo Clinic research that found the rapid breakdown of unsaturated fat can worsen the course of severe acute pancreatitis leading to increased toxicity, organ failure and death.
Patients with acute pancreatitis who develop COVID-19 may experience increased inflammation, putting them at a higher risk for further complication. The development of RABI-767 may aid in the understanding of the role fatty acids play in the virus.
"We have accelerated the development by tailoring the business around the science — not the other way around. When we get approval, our drug RABI-767 will be the first and only drug to be delivered via intraperitoneal injection, to preserve the science and the mechanism of action that ensure drug efficacy," Gabi Hanna, MD, CEO of Lamassu Pharma said in the release.
Lamassu anticipates clinical trial approval within the next few months and are closely monitoring COVID-19 variants to tailor future research toward the treatment of patients with COVID-19 specifically.